Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

AI Briefing

• – Vertex Pharmaceuticals' ALYFTREK and TRIKAFTA approved for expanded use in CF patients with specific gene variant.
• – Expanded approval allows treatment of ~95% of CF patients in the US.
• – US FDA approval expands availability of these medicines to individuals with CF ages 6 and older.